YTHDF1 promotes gallbladder cancer progression via post‐transcriptional regulation of the m6A / UHRF1 axis
Journal of Cellular and Molecular Medicine · 2024-05 · 28 (9)
DOI: 10.1111/jcmm.18328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 29.04.2024. Verfasst von Jiemin Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Complex Severe and Rare Diseases, Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical…. Hauptthemen laut MEDLINE: Adenosine, Gallbladder Neoplasms, Gene Expression Regulation, Neoplastic, RNA-Binding Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine, National Key Clinical Specialty Construction Project, National Key Research and Development Program of China.
Abstract (Originalsprache)
Gallbladder cancer is a rare but fatal malignancy. However, the mechanisms underlying gallbladder carcinogenesis and its progression are poorly understood. The function of m6A modification and its regulators was still unclear for gallbladder cancer. The current study seeks to investigate the function of YTH m6A RNA‐binding protein 1 (YTHDF1) in gallbladder cancer. Transcriptomic analysis and immunochemical staining of YTHDF1 in gallbladder cancer tissues revealed its upregulation compared to paracancerous tissues. Moreover, YTHDF1 promotes the proliferation assays, Transwell migration assays, and Transwell invasion assays of gallbladder cancer cells in vitro. And it also increased tumour growth in xenograft mouse model and metastases in tail vein injection model in vivo. In vitro, UHRF1 knockdown partly reversed the effects of YTHDF1 overexpression. Mechanistically, dual‐luciferase assays proved that YTHDF1 promotes UHRF1 expression via direct binding to the mRNA 3′‐UTR in a m6A‐dependent manner. Overexpression of YTHDF1 enhanced UHRF1 mRNA stability, as demonstrated by mRNA stability assays, and Co‐IP studies confirmed a direct interaction between YTHDF1 and PABPC1. Collectively, these findings provide new insights into the progression of gallbladder cancer as well as a novel post‐transcriptional mechanism of YTHDF1 via stabilizing target mRNA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Complex Severe and Rare Diseases, Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
- State Key Laboratory of Complex Severe and Rare Diseases, Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Xiaodong He
Förderung
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- National Key Clinical Specialty Construction Project
- National Key Research and Development Program of China
- National High-Level Hospital Clinical Research Funding
Zitieren
APA
Chen, J., Bai, X., Zhang, W., Yan, Z., Liu, Y., Zhou, S., Wu, X., He, X., & Yang, A. (2024). YTHDF1 promotes gallbladder cancer progression via post‐transcriptional regulation of the m6A / UHRF1 axis. Journal of Cellular and Molecular Medicine, 28(9). https://doi.org/10.1111/jcmm.18328
Vancouver
Chen J, Bai X, Zhang W, Yan Z, Liu Y, Zhou S, et al. YTHDF1 promotes gallbladder cancer progression via post‐transcriptional regulation of the m6A / UHRF1 axis. Journal of Cellular and Molecular Medicine. 2024;28(9). doi:10.1111/jcmm.18328
BibTeX
@article{Chen2024,
author = {Chen, Jiemin and Bai, Xuesong and Zhang, Wenqin and Yan, Zhiyu and Liu, Yongru and Zhou, Shengnan and Wu, Xi and He, Xiaodong and Yang, Aiming},
title = {YTHDF1 promotes gallbladder cancer progression via post‐transcriptional regulation of the m6A / UHRF1 axis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {9},
doi = {10.1111/jcmm.18328}
}
EUVIMED